[1][2] It is a non-opioid, small-molecule analgesic that works as a selective inhibitor of Nav1.8-dependent pain-signaling pathways in the peripheral nervous system,[3][4] avoiding the addictive potential of opioids.

[1] The most common adverse reactions include itching, muscle spasms, increased blood level of creatine kinase, and rash.

[10] The efficacy of suzetrigine was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, one following abdominoplasty and the other following bunionectomy.

[1][2] Common adverse effects of suzetrigine may include itching, rash, muscle spasms, and increased levels of creatine kinase.

[1][2] Suzetrigine operates on peripheral nerves, avoiding the addictive potential of opioids which affect the central nervous system.

[3] Vertex Pharmaceuticals announced in January 2024 that suzetrigine had successfully met several endpoints in its Phase III clinical trials.